000180028 001__ 180028
000180028 005__ 20240229145603.0
000180028 0247_ $$2doi$$a10.1002/ijc.34131
000180028 0247_ $$2pmid$$apmid:35603902
000180028 0247_ $$2ISSN$$a0020-7136
000180028 0247_ $$2ISSN$$a1097-0215
000180028 0247_ $$2altmetric$$aaltmetric:129786848
000180028 037__ $$aDKFZ-2022-01045
000180028 041__ $$aEnglish
000180028 082__ $$a610
000180028 1001_ $$0P:(DE-He78)857bbcdb8f5f582e00795df8b957767d$$avon Knebel Doeberitz, Nikolaus$$b0$$eFirst author$$udkfz
000180028 245__ $$aChanging paradigms in oncology: toward non-cytotoxic treatments for advanced gliomas.
000180028 260__ $$aBognor Regis$$bWiley-Liss$$c2022
000180028 3367_ $$2DRIVER$$aarticle
000180028 3367_ $$2DataCite$$aOutput Types/Journal article
000180028 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663599284_5887$$xReview Article
000180028 3367_ $$2BibTeX$$aARTICLE
000180028 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180028 3367_ $$00$$2EndNote$$aJournal Article
000180028 500__ $$a#EA:E010# / 2022 Nov 1;151(9):1431-1446
000180028 520__ $$aGlial-lineage malignancies (gliomas) recurrently mutate and/or delete the master regulators of apoptosis p53 and/or p16/CDKN2A, undermining apoptosis-intending (cytotoxic) treatments. By contrast to disrupted p53/p16, glioma cells are live-wired with the master transcription factor circuits that specify and drive glial lineage-fates: these transcription factors activate early-glial and replication programs as expected, but fail in their other usual function of forcing onward glial lineage-maturation - late-glial genes have constitutively 'closed' chromatin requiring chromatin-remodeling for activation - glioma-genesis disrupts several epigenetic components needed to perform this work, and simultaneously amplifies repressing epigenetic machinery instead. Pharmacologic inhibition of repressing epigenetic enzymes thus allows activation of late-glial genes and terminates glioma self-replication (self-replication = replication without lineage-maturation), independent of p53/p16/apoptosis. Lineage-specifying master transcription factors therefore contrast with p53/p16 in being enriched in self-replicating glioma cells, reveal a cause-effect relationship between aberrant epigenetic repression of late-lineage programs and malignant self-replication, and point to specific epigenetic targets for non-cytotoxic glioma-therapy.
000180028 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000180028 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180028 650_7 $$2Other$$aCancer Epigenetics
000180028 650_7 $$2Other$$aEpigenetic Glioma Therapy
000180028 650_7 $$2Other$$aGlioma
000180028 650_7 $$2Other$$aGlioma Therapy
000180028 650_7 $$2Other$$aNeurooncology
000180028 7001_ $$0P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aPaech, Daniel$$b1$$udkfz
000180028 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b2$$udkfz
000180028 7001_ $$0P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aPusch, Stefan$$b3$$udkfz
000180028 7001_ $$aTurcan, Sevin$$b4
000180028 7001_ $$aSaunthararajah, Yogen$$b5
000180028 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34131$$gp. ijc.34131$$n9$$p1431-1446$$tInternational journal of cancer$$v151$$x0020-7136$$y2022
000180028 909CO $$ooai:inrepo02.dkfz.de:180028$$pVDB
000180028 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)857bbcdb8f5f582e00795df8b957767d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180028 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180028 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180028 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180028 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000180028 9141_ $$y2022
000180028 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-04$$wger
000180028 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000180028 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000180028 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000180028 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-25$$wger
000180028 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2021$$d2022-11-25
000180028 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2021$$d2022-11-25
000180028 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000180028 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x1
000180028 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000180028 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000180028 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x4
000180028 9200_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000180028 980__ $$ajournal
000180028 980__ $$aVDB
000180028 980__ $$aI:(DE-He78)E010-20160331
000180028 980__ $$aI:(DE-He78)B360-20160331
000180028 980__ $$aI:(DE-He78)HD01-20160331
000180028 980__ $$aI:(DE-He78)B300-20160331
000180028 980__ $$aI:(DE-He78)B062-20160331
000180028 980__ $$aUNRESTRICTED